DESTINY-CRC02 Phase 2 Trial of ENHERTU® Initiated in Patients with HER2 Overexpressing Advanced Colorectal Cancer
MUNICH & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca today announced that the first patient...






